Duhao Net helps individual entrepreneurs and enterprises find high-quality suppliers, reduce procurement costs, and make transactions easier.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Anti-tumor drug supplier

Release time：2024-09-28 22:02:02 Source：DuHao

Tel : +86-400-828-3900

Email: net.fei@163.com

Address: No.7 Kunlunshan Road, Lianyungang Economic and Technological Development Zone, Jiangsu Province, China

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading global pharmaceutical company headquartered in China, renowned for its focus on the research, development, manufacturing, and commercialization of high-quality healthcare products. Established with innovation as its core development strategy, Hengrui has concentrated its R&D efforts on a variety of therapeutic areas including antineoplastic drugs, surgical medications, and treatments for autoimmune, metabolic, and cardiovascular diseases.

Global Recognition

Hengrui Pharma has consistently gained recognition on the world stage. For six consecutive years, it has been included in Pharma Exec's annual list of the top 50 global pharmaceutical companies. In 2021, it was ranked 24th among the top 1,000 global pharmaceutical companies by Torreya, and in 2024, it placed 8th in Citeline's "Top 25 Global Pharma Companies by Pipeline Size."

R&D and Innovation

Hengrui’s commitment to innovation is reflected in its substantial R&D investments. In recent years, the company has allocated more than $5 billion USD (over 40 billion RMB) towards research and development, establishing a team of more than 5,000 highly skilled professionals across 14 R&D centers worldwide. The company also has subsidiaries in key international markets, including the United States, European Union, Australia, and Japan.

As of June 2024, Hengrui has filed 2,527 patent applications, with 585 patents granted in China and 705 granted worldwide, including in the US, EU, and Japan. Hengrui's innovative pipeline includes 15 in-house developed products and 2 in-licensed products that are marketed in China, more than 90 innovative candidates in the R&D stage, and nearly 20 products in clinical development globally.

International Expansion

Internationalization is a key pillar of Hengrui’s strategy. By the end of 2023, its products had entered over 40 countries, including the US, EU, and Japan, adhering to high regulatory standards such as those of the US and European Pharmacopoeia. Hengrui exports a wide range of products, including injections and oral preparations, to international markets. Through its global partnerships, the company has secured nearly 20 product approvals in these regions, enhancing its footprint in both regulated and emerging markets.

The company actively collaborates with international partners to bring its innovations to market. Notable collaborations include a €1.4 billion partnership with Merck and a US$6 billion licensing deal with Hercules for the GLP-1 product portfolio (HRS-7535, HRS-9531, and HRS-4729). These agreements illustrate Hengrui's ability to advance its R&D findings through global alliances.

Therapeutic Focus and Major Products

Hengrui is committed to improving treatments in oncology, metabolic diseases, autoimmune diseases, cardiovascular diseases, and other therapeutic areas. The company's innovative products include:

Aitan (Apatinib Mesylate Tablets): A Class 1 innovative drug for advanced gastric cancer and hepatocellular carcinoma.
Aido (Sulfopegfilgrastim Injection): The first G-CSF product developed in China for neutropenia during chemotherapy.
Airini (Pyrotinib Maleate Tablets): An anti-HER1/HER2/HER4 targeted drug for breast cancer.
Erica (Carrelizumab Injection): A PD-1 monoclonal antibody with nine approved indications across various cancers.
Ai Ruiyi (Fluzoparib Capsules): The first PARP inhibitor in China for ovarian cancer treatment.

Mission and Vision

Hengrui’s mission is to promote a healthier life for humanity through scientific advancements. Its vision is to become a global biopharmaceutical leader driven by innovation. The company upholds core values of innovation, pragmatism, focus, and diligence, ensuring steady progress in delivering groundbreaking therapies to patients worldwide.

Future Outlook

Hengrui aims to continue its innovation journey, expanding its R&D pipeline and strengthening its international presence. With ongoing collaborations, strategic investments, and a robust product pipeline, the company is well-positioned to meet the healthcare needs of patients globally and advance the development of novel therapies in key therapeutic areas.

Duhao Net